Comparison of joint destruction between standard- and low-dose etanercept in rheumatoid arthritis from the Prevention of Cartilage Destruction by Etanercept (PRECEPT) study.

@article{Tada2012ComparisonOJ,
  title={Comparison of joint destruction between standard- and low-dose etanercept in rheumatoid arthritis from the Prevention of Cartilage Destruction by Etanercept (PRECEPT) study.},
  author={Masahiro Tada and Tatsuya Koike and Tadashi Okano and Yuko Sugioka and Shigeyuki Wakitani and Kenzo Fukushima and Akira Sakawa and Kazunori Uehara and Kentaro Inui and Hiroaki Nakamura},
  journal={Rheumatology},
  year={2012},
  volume={51 12},
  pages={2164-9}
}
OBJECTIVE To evaluate the prevention of joint destruction and clinical efficacy of low-dose etanercept (ETN) (25 mg/week) compared with standard-dose ETN (50 mg/week) in RA. METHODS In this prospective, randomized, open-label study, 70 patients were assigned to receive ETN at either 50 or 25 mg/week for 52 weeks. The primary endpoint was the variation in… CONTINUE READING